Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial

PURPOSE: To find the best short-term daily recombinant human erythropoietin (rhEPO)-based treatment protocols for blood-saving purpose in THA. METHOD: The patients were randomized to 1 of 3 interventions: Patients in group A received 10,000 IU (150 IU/kg) of subcutaneous rhEPO (1 ml) daily from 5 da...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Mingcheng, Tao, Qifeng, Wang, Duan, Wang, Haoyang, Zhou, Zongke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917634/
https://www.ncbi.nlm.nih.gov/pubmed/35279105
http://dx.doi.org/10.1186/s12891-022-05184-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917634/
https://www.ncbi.nlm.nih.gov/pubmed/35279105
http://dx.doi.org/10.1186/s12891-022-05184-1

Ejemplares similares